Literature DB >> 8312674

Rheumatoid arthritis in the aged. Incidence and optimal management.

G Nesher1, T L Moore.   

Abstract

Rheumatoid arthritis (RA) is estimated to occur in 0.3 to 3% of the general population. Up to one-third of RA patients first present for treatment after the age of 60 years (elderly-onset RA). The overall frequency in individuals older than 65 is increased, so that 30 to 40% of RA patients treated in rheumatology centres are > 60 years of age. Optimal management of all RA patients includes physical therapy, medications, both nonsteroidal anti- inflammatory drugs (NSAIDs) and remittive agents, and, in some cases, surgery. In the elderly, these treatment modalities at times need to be altered to accommodate age-related changes in body mechanics and organ function. Thus, the approach to physical therapy in older patients is different than in the young. There are fewer rest periods and more passive exercises. Drug treatment must also be modified, since NSAIDs and several remittive agents are more hazardous in elderly patients. Indications for orthopaedic procedures may also be different. The long term management of RA requires a delicate balance of benefit and risk. It is wise to begin with the least toxic medications. However, if necessary, potentially toxic medications can be given cautiously, with close monitoring for adverse effects.

Entities:  

Mesh:

Year:  1993        PMID: 8312674     DOI: 10.2165/00002512-199303060-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  151 in total

1.  Abolition by omeprazole of aspirin induced gastric mucosal injury in man.

Authors:  T K Daneshmend; A G Stein; N K Bhaskar; C J Hawkey
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

2.  Rheumatoid arthritis in the aged.

Authors:  G E Ehrlich; W A Katz; S H Cohen
Journal:  Geriatrics       Date:  1970-02

3.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

4.  Non-steroidal anti-inflammatory drugs and peptic ulcer perforation.

Authors:  D S Collier; J A Pain
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

5.  The effect of age on methotrexate efficacy and toxicity.

Authors:  F Wolfe; M A Cathey
Journal:  J Rheumatol       Date:  1991-07       Impact factor: 4.666

6.  Interferon gamma in rheumatoid arthritis--a double blind study comparing human recombinant interferon gamma with placebo.

Authors:  E M Veys; H Mielants; G Verbruggen; J P Grosclaude; W Meyer; A Galazka; J Schindler
Journal:  J Rheumatol       Date:  1988-04       Impact factor: 4.666

7.  Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin.

Authors:  G Ciabattoni; G A Cinotti; A Pierucci; B M Simonetti; M Manzi; F Pugliese; P Barsotti; G Pecci; F Taggi; C Patrono
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

8.  Gold therapy in the elderly rheumatoid arthritis patient.

Authors:  W F Kean; N Bellamy; P M Brooks
Journal:  Arthritis Rheum       Date:  1983-06

9.  Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.

Authors:  R S Ehsanullah; M C Page; G Tildesley; J R Wood
Journal:  BMJ       Date:  1988-10-22

10.  Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.

Authors:  G Horneff; G R Burmester; F Emmrich; J R Kalden
Journal:  Arthritis Rheum       Date:  1991-02
View more
  9 in total

Review 1.  Safety considerations in treating concomitant diseases in patients with asthma.

Authors:  L W Hunt
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

Review 2.  Neutropenia in the Elderly: A Rheumatology Perspective.

Authors:  Su-Ann Yeoh; Christine Fox; Richard Hull
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

3.  Arthritic disease is more severe in older rats in a kaolin/carrageenan-induced arthritis model.

Authors:  Kyoung Soo Kim; Myung-Hwan Kim; Mijung Yeom; Hyun Mi Choi; Hyung-In Yang; Myung Chul Yoo; Dae-Hyun Hahm
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

Review 4.  Optimising low-dose methotrexate for rheumatoid arthritis-A review.

Authors:  Catherine J Lucas; Simon B Dimmitt; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

5.  Safety of low dose methotrexate in elderly patients with rheumatoid arthritis.

Authors:  B Hirshberg; M Muszkat; O Schlesinger; A Rubinow
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 6.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 7.  Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

Authors:  Roy Fleischmann; Imran Iqbal
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 8.  Cyclosporin pharmacokinetics in the elderly.

Authors:  J M Kovarik; E U Koelle
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 4.271

Review 9.  Slipping through the Cracks: Linking Low Immune Function and Intestinal Bacterial Imbalance to the Etiology of Rheumatoid Arthritis.

Authors:  Kuniaki Terato; Christopher T Do; Hiroshi Shionoya
Journal:  Autoimmune Dis       Date:  2015-03-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.